ストックスクリーナーアプリを入手
5.10
2.11%
-0.11
Evommune Inc (EVMN) 最新ニュース
Evommune stock initiated at Overweight by Morgan Stanley on dermatitis drug potential - Investing.com
Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight - GlobeNewswire Inc.
Evommune, Inc. $EVMN Stock: Andera Partners Decreases Stake - MarketBeat
Evommune, Inc. (EVMN) options chain - Yahoo Finance Australia
Form 4 Evommune Inc: Luis C. Pena (Director, President & CEO) For: 30 September - Investing.com India
Form 4 Evommune Inc: Luis C. Pena (Director, President & CEO) For: 30 September By Investing.com - Investing.com South Africa
At 85% of the closing price, Evommune (EVMN) CEO acquires 1,115 shares through an employee plan. - Stock Titan
Evommune, Inc. (EVMN) Options Chain - Yahoo! Finance Canada
Evommune (NYSE:EVMN) Stock Bumped Up to "Hold" by UBS Group - MarketBeat
Evommune, Inc. (EVMN) Receives a Hold from UBS - The Globe and Mail
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target - Moomoo
UBS Initiates Coverage on Evommune With Neutral Rating, $8 Price Target - Yahoo Finance
UBS Initiates Evommune(EVMN.US) With Hold Rating, Announces Target Price $8 - Moomoo
UBS initiates Evommune stock coverage with neutral rating on AD potential - Investing.com Nigeria
Long-acting EVO301 Shows Promise in Proof-of-concept AD Study - The Dermatology Digest
Evommune Inc (EVMN-N) Stock Price and News - The Globe and Mail
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - BioSpace
Evommune presents Phase 2a atopic dermatitis trial data - Investing.com
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Yahoo! Finance Canada
Evommune (NYSE:EVMN)Stock Analysis - Simply Wall Street
Evommune, Inc. (NYSE:EVMN) Stock Has Average Target Price of $33.33 According to Analysts - MarketBeat
Evommune Reports Phase 2a EVO301 Atopic Dermatitis Data at EADV 2026 via 8-K Filing - Kalkine Media
Evommune to present phase 2a atopic dermatitis data at EADV By Investing.com - Investing.com Nigeria
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - Yahoo Finance Australia
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress - Yahoo Finance
Evommune: Pipeline Reset After EVO756 Failure, All Eyes On EVO301 (NYSE:EVMN) - Seeking Alpha
Analysts Have Conflicting Sentiments on These NA Companies: Evommune, Inc. (EVMN) and Douglas AG (OtherDOUDF) - The Globe and Mail
Cantor Fitzgerald reiterates Evommune stock rating at Overweight - Investing.com
Evommune (EVMN) Drops EVO756 for Eczema. Can EVO301 Carry the Pipeline? - Yahoo Finance
Evommune posts updated corporate presentation outlining pipeline progress, cash runway and 2027–2028 milestones - TradingView
Evommune（NYSE: EVMN）が現金を賢明に活用することを期待しています。 - Moomoo
Analysts Offer Insights on NA Companies: Chime Financial, Inc. Class A (CHYM), ServiceTitan, Inc. Class A (TTAN) and Evommune, Inc. (EVMN) - The Globe and Mail
Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL) - The Globe and Mail
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Australia
Evommune Scraps Itch Drug After Second Phase 2 Failure, Stock Slides 18% - finance.biggo.com
EVMN Maintains Rating by Leerink Partners -- Price Target Lowered to $22 - GuruFocus
Evommune Drops AD Program Following Phase 2B Trial Failure - The Dermatology Digest
Why this company's stock took a hit just 10 months after its IPO - The Business Journals
Evommune’s EVO-756 fails dermatitis study; focus on migraine - BioWorld News
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Nigeria
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com Canada
Stifel reiterates Evommune stock rating after phase 2b trial miss By Investing.com - Investing.com India
Stifel reiterates Evommune stock rating after phase 2b trial miss - Investing.com
Evommune Reports EVO756 Phase 2b Trial Failure in Atopic Dermatitis, Halts Development for This Indication - Kalkine Media
Evommune (NYSE:EVMN) Price Target Lowered to $21.00 at Royal Bank Of Canada - MarketBeat
RBC cuts Evommune stock price target on drug trial setback By Investing.com - Investing.com Canada
Why is Evommune stock plunging today? By Investing.com - Investing.com Australia
RBC cuts Evommune stock price target on drug trial setback - Investing.com
Evommune's (EVMN) Neutral Rating Reaffirmed at HC Wainwright - MarketBeat
3.09%
0.72%
大文字化:
|
ボリューム (24 時間):